Onward Medical NV ONWD

BRU: ONWD | ISIN: NL0015000HT4   2/04/2026
3,235 EUR (-5,27%)
(-5,27%)   2/04/2026

1 april 2026 · ONWARD Medical Publishes Convocation of the 2026 Annual General Meeting of Shareholders and Proposed Resolutions · Persbericht

31 maart 2026 · ONWARD Medical Reports Full Year 2025 Financial and Operating Results, Highlighting Strong US Commercial Performance and Major Pipeline Milestones · Persbericht

23 maart 2026 · ONWARD Medical Schedules Webcast to Report Full-Year 2025 Financial Results and Provide Business Update · Persbericht

4 februari 2026 · ONWARD Medical Announces First Participant Enrolled in Global Pivotal Study Evaluating ARC-IM System to Address Blood Pressure Instability After Spinal Cord Injury · Persbericht

23 januari 2026 · ONWARD Medical Appoints Ali Kiboro as Chief Financial Officer · Persbericht

22 januari 2026 · ONWARD Medical Completes Two Additional Brain-Computer Interface Implants Paired with Spinal Cord Stimulation Technology to Restore Thought-Driven Movement · Persbericht

24 november 2025 · ONWARD Medical Drives Strong US ARC-EX Adoption and Achieves Important Scientific and Regulatory Milestones in Q3 2025 · Persbericht

17 november 2025 · ONWARD Medical Receives FDA 510(k) Clearance Expanding ARC-EX System Indication for Home Use · Persbericht

28 oktober 2025 · ONWARD Medical Publishes Closing of Bookbuild Offering · Persbericht

24 oktober 2025 · ONWARD Medical Successfully Raises Over EUR 50 Million in Capital Increase · Persbericht

22 oktober 2025 · ONWARD Medical Launches Capital Increase for Indicative Amount of EUR 50 Million · Persbericht

13 oktober 2025 · ONWARD Medical Provides Preliminary Q3 2025 Update Highlighting Accelerating ARC-EX Adoption in the United States · Persbericht

8 oktober 2025 · Portzamparc – BNP Paribas Group Initiates Coverage of ONWARD Medical with a Buy Rating and Target Price of EUR 10.20 · Persbericht

8 oktober 2025 · Portzamparc – Groupe BNP Paribas initie la couverture d’ONWARD Medical avec une recommandation d’Achat et un objectif de cours de 10,20 EUR · Persbericht

18 september 2025 · Concurrent Publications in Nature and Nature Medicine Highlight Advances in Blood Pressure Regulation after Spinal Cord Injury Using ONWARD ARC-IM Therapy · Persbericht

8 september 2025 · ONWARD Medical Receives CE Mark for ARC-EX, Enabling Commercial Launch of Breakthrough Spinal Cord Stimulation System in Europe · Persbericht

2 september 2025 · ONWARD Medical Demonstrates Commercial Traction and Advances Pipeline in the First Half of 2025 · Persbericht

18 augustus 2025 · ONWARD Medical Receives FDA IDE Approval to Initiate the Empower BP Pivotal Study with the ARC-IM System · Persbericht

6 augustus 2025 · ONWARD Medical annonce la nomination de Lucas Buchanan à son conseil d’administration · Persbericht

6 augustus 2025 · ONWARD Medical Announces the Appointment of Lucas Buchanan to its Board of Directors · Persbericht

Mijn selecties